<DOC>
	<DOCNO>NCT01297504</DOCNO>
	<brief_summary>The study design gather information regarding use palivizumab prophylaxis respiratory syncytial virus ( RSV ) infection high-risk infant select country within Latin America .</brief_summary>
	<brief_title>A One-Year Observation Palivizumab Infants Risk Respiratory Syncytial Virus Infection Latin America</brief_title>
	<detailed_description>RSV cause significant disease . There paucity data develop country even though exist data clearly indicate RSV account high proportion acute respiratory illness ( ARIs ) child . This multi-center study cohort infant risk RSV infection Latin America receive palivizumab usual manner accordance term market authorization regard dose , population indication . Enrolled participant follow one year first dose palivizumab . Epidemiological clinical data well information compliance , hospitalization safety collect .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>Children history bronchopulmonary dysplasia , infant history prematurity ( less equal 35 week gestational age ) , child hemodynamically significant congenital heart disease receive first dose palivizumab within 2 week prior signature Informed Consent Form . Parent legal guardian child provide write Informed Consent Children exclude receive palivizumab per local guideline</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>palivizumab</keyword>
	<keyword>low respiratory tract infection</keyword>
	<keyword>Respiratory syncytial virus</keyword>
	<keyword>usage pattern</keyword>
</DOC>